Having trouble accessing articles? Reset your cache.

Abiraterone meets prostate cancer endpoint

Johnson & Johnson (NYSE:JNJ) said it unblinded the Phase III COU-AA-301 trial to treat metastatic castration-resistant prostate cancer

Read the full 183 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE